Clinical Trial Search

Primary: Frequency and Causality of Serious Adverse Events (SAEs), Non-Serious Adverse Events (NSAEs) and Grade ≥3 Adverse Events (AEs) to AST-VAC2 — 0; 97; 3; 0 Adverse Events

Primary: Pharmacokinetics Parameter - Area Under the Concentration-Time Curve to Infinity (AUCinf) of PF-07081532 — 179400; 178300 nanogram*hour/milliliter (ng*hr/mL)

Primary: Neuropathic Pain Monthly Score: Change From Baseline to Month 6 — -1.64; -2.05 score on a scale — p=0.3189

Primary: Clinical Benefit Rate (CBR) for ZN-c5 as a Monotherapy — 7; 0; 1; 1 Participants

Primary: PVI Analyzer Sensitivity and Specificity, Measured as the Accuracy of Predictions for Non-isolated and Isolated Veins. — 216; 215 Electrogram (EGM) — p=0.006

Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: Liking: Difference Score in Liking/Wanting of Each E-cigarette Condition — 1.268; -3.916 score on a scale — p=0.053

Primary: Number of Subjects With Event First Moderate or Severe COPD Exacerbations After Index Date — 424; 375 Participants

Primary: Mean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B). — -8.5…

Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…

Primary: Disease Control Rate — 5; 1; 0; 0 Participants

Primary: Number of Participants With Annual Influenza Vaccine Among Index Patients — 20689; 20570; 10374; 10317 Participants

Primary: Peak Plasma Concentration (Cmax) of ACER-801 — 10.78; 32.36; 41.75 ng/mL

Primary: Patient / Caregiver Satisfaction Scores — 0; 0; 4; 4 Participants